← board
LENZ
distress 5/10 · elevated risk$5.26-1%today-89% from 52w high
Revenue
pre-revenue
Liquidity
$25M
Runway
0.3 yrs
Shares 1y
+10%
Price & events
-75.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+7.8%
1W
-8.5%
1M
-42.5%
3M
-74.3%
6M
-84.1%
1Y
-77.0%
2Y
-93.6%
5Y
-91.5%
All
Overview
- Market Cap
- $164.92M
- Volume
- 87.35K
- 52 Week Range
- $4.88 – $49.05
- Total Shares
- 31.35M
- Float Shares
- 16.88M
- Short %
- 54.81%
- % Held by Insiders
- 2.65%
- % Held by Institutions
- 109.70%
- RVOL
- 0.09x
- Beta
- 1.62
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-12-12safety signalVIZZ (aceclidine ophthalmic solution) 1.44% · Retinal tear reported in patient with pre-existing retinal pathology; company does not see causal link and safety expectations unchanged.SEC 8-K
- August 12, 2024regulatory submissionFiled (NDA/BLA)LNZ100 · NDA submission to FDASEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $32 (+508% upside) · 7 analysts
- 2026-07-07HC Wainwright & Co.Buy
- 2026-05-13CitigroupBuy
- 2026-05-12HC Wainwright & Co.Buy
- 2026-05-12Piper SandlerOverweight → Neutral
- 2026-04-21HC Wainwright & Co.Buy
- 2026-03-26CitigroupBuy
Competitors
- none identified
Recent news
- 2026-07-22Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline - Yahoo Finance
- 2026-07-22LENZ Therapeutics (LENZ) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
- 2026-07-22LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
- 2026-07-22LENZ Therapeutics (LENZ) TD Cowen 46th Annual Health Care Conference Summary - Quartr
- 2026-07-21LENZ Therapeutics (LENZ) Leerink Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-21LENZ Therapeutics (LENZ) Proxy filing Summary - Quartr
- 2026-07-16We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely - Sahm
- 2026-07-10LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.